Provided by Tiger Trade Technology Pte. Ltd.

Jasper Therapeutics

1.23
+0.01000.82%
Post-market: 1.230.00000.00%17:48 EDT
Volume:216.34K
Turnover:267.18K
Market Cap:34.42M
PE:-0.21
High:1.27
Open:1.22
Low:1.21
Close:1.22
52wk High:7.19
52wk Low:1.11
Shares:27.98M
Float Shares:22.81M
Volume Ratio:0.86
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.7868
EPS(LYR):-4.8865
ROE:-191.12%
ROA:-72.92%
PB:2.97
PE(LYR):-0.25

Loading ...

CoreWeave Bulls Should Brace For 'Wild, Lumpy, Volatile Ride,' JPMorgan Says

Benzinga_recent_news
·
Nov 11, 2025

RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Nov 11, 2025

Jasper Therapeutics (JSPR) Receives a Hold from William Blair

TIPRANKS
·
Nov 11, 2025

Positive Outlook on Jasper Therapeutics: Strong Drug Efficacy and Financial Stability Support Buy Rating

TIPRANKS
·
Nov 11, 2025

Buy Rating Affirmed for Jasper Therapeutics Amid Promising Clinical Trial Results and Proactive Development Efforts

TIPRANKS
·
Nov 11, 2025

Jasper Therapeutics Q3 loss smaller than estimates

Reuters
·
Nov 10, 2025

Jasper Therapeutics Q3 EPS $(1.13) Beats $(1.28) Estimate

Benzinga
·
Nov 10, 2025

Jasper Therapeutics posts $18.7 million net loss for third quarter 2025

Reuters
·
Nov 10, 2025

Jasper Therapeutics Inc - Plan to Report Initial Data From Etesian Study in Allergic Asthma in Q4

THOMSON REUTERS
·
Nov 10, 2025

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Nov 10, 2025

Jasper Therapeutics to Present at UBS Global Healthcare Conference

Reuters
·
Nov 04, 2025

Jasper Therapeutics Inc expected to post a loss of $1.21 a share - Earnings Preview

Reuters
·
Nov 03, 2025

Jasper Therapeutics Advances Briquilimab Study for Chronic Urticaria

TIPRANKS
·
Oct 28, 2025

Jasper Therapeutics Highlights Promising Briquilimab Data in Chronic Urticaria and Other Inflammatory Diseases in Latest Corporate Presentation

Reuters
·
Oct 14, 2025

Director Svetlana Lucas Reports Acquisition of Common Shares of Jasper Therapeutics Inc

Reuters
·
Sep 25, 2025

Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP

TIPRANKS
·
Sep 22, 2025

Jasper Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Sep 22, 2025

U.S. RESEARCH ROUNDUP-Apple, GE Aerospace, Tesla

Reuters
·
Sep 22, 2025

Jasper Therapeutics Inc : Btig Cuts Target Price to $7 From $20

THOMSON REUTERS
·
Sep 22, 2025

BTIG Remains a Buy on Jasper Therapeutics (JSPR)

TIPRANKS
·
Sep 20, 2025